Edition:
United Kingdom

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

88.60USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$88.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
357,691
52-wk High
$126.15
52-wk Low
$64.73

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2018 Sep '18 151.76 0.524
Jun '18 96.90 -0.066
Mar '18 71.09 -0.467
FY 2017 Dec '17 94.52 0.078
Sep '17 60.77 -0.126
Jun '17 6.34 -0.681
Mar '17 0.00 -0.897
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Mar-19 6 141.07 158.00 132.30 105.04
Quarter Ending Jun-19 6 153.48 161.80 136.90 152.59
Year Ending Dec-19 16 640.43 710.50 531.60 622.24
Earnings (per share)
Quarter Ending Mar-19 8 0.20 0.39 0.08 0.18
Quarter Ending Jun-19 8 0.30 0.53 0.03 0.63
Year Ending Dec-19 16 1.62 2.86 0.63 2.05
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 69.71 33.71
P/E High - Last 5 Yrs. 99.65 148.01 49.93
P/E Low - Last 5 Yrs. 99.65 47.79 24.27
Beta 0.34 1.08 0.90
Price to Sales (TTM) 869.54 49.51 6.28
Price to Book (MRQ) 15.95 10.16 5.27
Price to Tangible Book (MRQ) 15.96 13.82 6.79
Price to Cash Flow (TTM) -- 52.80 24.84
% Owned Institutions -- 3.75 1.69

Dividends

  Company industry sector
Dividend Yield -- 0.12 1.40
Dividend Yield - 5 Year Avg 0.00 0.09 1.42
Dividend 5 Year Growth Rate -- 0.79 4.83
Payout Ratio(TTM) -- 7.04 41.08

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -- 130.04 9.72
Sales (TTM) vs TTM 1 Yr. Ago -57.77 47.85 5.87
Sales - 5 Yr. Growth Rate -27.98 22.76 11.20
EPS (MRQ) vs Qtr. 1 Yr. Ago -46.61 75.87 47.26
EPS (TTM) vs TTM 1 Yr. Ago -76.24 -- --
EPS - 5 Yr. Growth Rate -- 12.03 10.82
Capital Spending - 5 Yr. Growth Rate 40.51 9.25 15.18

Financial Strength

  Company industry sector
Quick Ratio (MRQ) 19.36 2.18 2.26
Current Ratio (MRQ) 19.36 3.43 3.08
LT Debt to Equity (MRQ) 104.47 18.73 11.38
Total Debt to Equity (MRQ) 104.47 31.43 16.13
Interest Coverage (TTM) -- -43.27 29.51

Profitability Ratios

  Company industry sector
Gross Margin (TTM) 99.04 56.29 53.78
Gross Margin - 5 Yr. Avg. -- 60.55 52.17
EBITD Margin (TTM) -3,472.08 -- --
EBITD - 5 Yr. Avg -383.57 -110.00 12.88
Operating Margin (TTM) -3,502.56 -184.42 6.20
Operating Margin - 5 Yr. Avg. -389.98 -126.43 8.32
Pre-Tax Margin (TTM) -3,470.51 -175.20 7.17
Pre-Tax Margin - 5 Yr. Avg. -365.11 -132.58 8.62
Net Profit Margin (TTM) -3,470.51 -181.93 3.30
Net Profit Margin - 5 Yr. Avg. -365.11 -136.98 4.89
Effective Tax Rate (TTM) -- 21.48 22.88
Effective Tax Rate - 5 Yr. Avg. -- 15.57 23.39

Efficiency

  Company industry sector
Revenue/Employee (TTM) 32,321 7,650,742 844,239,900
Net Income/Employee (TTM) -1,121,719 652,581 100,064,185
Receivable Turnover (TTM) -- 6.25 5.72
Inventory Turnover (TTM) -- 1.89 3.48
Asset Turnover (TTM) 0.01 0.32 0.93

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -37.14 6.45 11.08
Return on Assets - 5 Yr. Avg. -25.12 5.52 12.21
Return on Investment (TTM) -38.94 8.99 14.48
Return on Investment - 5 Yr. Avg. -27.35 6.85 15.88
Return on Equity (TTM) -60.54 10.13 15.99
Return on Equity - 5 Yr. Avg. -30.27 8.39 17.00
  1 Year 3 Year 5 Year
Sales % -24.12 72.56 -27.98
EPS (TTM) % -54.60 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Neurocrine Biosciences Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week 8.14 4.41 99 99
13 Week 33.62 27.11 99 95
26 Week 52.74 41.13 99 98
52 Week 31.26 11.25 99 72
YTD 61.34 41.69 99 72
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 0.00%
# of Holders: 460
Total Shares Held: 91,188,617
3 Mo. Net Change: -59,618
# New Positions: 5
# Closed Positions: 11
# Increased Positions: 21
# Reduced Positions: 27
# Net Buyers: -6
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.